DarioHealth Corp.
DarioHealth provides a digital health platform for chronic condition management, behavioral health and preventive care. It serves consumers directly and works with employers, health plans, pharmaceutical companies and providers. DarioHealth is based in New York, New York. Its offerings include Dario Connect for health education and engagement, Dario Mind for mental health, Dario Health for diabetes, hypertension and weight management, and Dario Move for musculoskeletal conditions. The platform combines digital self-care, connected devices, AI-driven personalization, virtual coaching and access to clinical care. DarioHealth earns subscription fees based on members or engaged members per month, with individual and bundled offerings. Some contracts include milestone-based payments or performance guarantees, while clinical services can also be paid for on a fee-for-service basis.
No SEC Form 4 filings for $DRIO in the last 30 days.
See all $DRIO insider activity →Stifel reduced its price target for DarioHealth to $5 from $10, a 50% decrease, while maintaining a Buy rating. The new target suggests a 203% upside from the Nov 12 close of $1.65, according to the firm.
DarioHealth reported Q3 2026 revenue of $5.3M, up 6% YoY. GAAP gross margin was 59%. Operating loss decreased 15% YoY. The company expects revenue acceleration in late 2026 and 2027, driven by new enterprise customers and multi-condition expansions. DarioHealth signed a major health plan in New Jersey, representing 1.5M covered lives. Cash reserves totaled $31.2M as of September 30, 2026.
DarioHealth (DRIO) appointed John R. Palumbo as Chairman of the Board, replacing Yoav Shaked, who remains a director. The change is effective immediately, according to an SEC filing.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DRIO (DarioHealth Corp.). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent DRIO coverage spans financial news, earnings and corporate actions.
Analyst downgrade suggests downside pressure on the stock.
Operating loss narrowed and revenue grew modestly, suggesting improving fundamentals.
Board chair change may cause modest short‑term volatility as investors reassess governance.
Board leadership change may cause modest stock movement as investors assess governance impact.
The appointment may signal strategic focus on payer‑consumer convergence, modestly supportive for the stock.
AlphAI scores every news story that mentions DRIO with an AI model for sentiment and relevance, and aggregates insider trades from DarioHealth Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel reduced its price target for DarioHealth to $5 from $10, a 50% decrease, while maintaining a Buy rating. The new target suggests a 203% upside from the Nov 12 close of $1.65, according to the firm.
DarioHealth reported Q3 2026 revenue of $5.3M, up 6% YoY. GAAP gross margin was 59%. Operating loss decreased 15% YoY. The company expects revenue acceleration in late 2026 and 2027, driven by new enterprise customers and multi-condition expansions. DarioHealth signed a major health plan in New Jersey, representing 1.5M covered lives. Cash reserves totaled $31.2M as of September 30, 2026.
DarioHealth (DRIO) appointed John R. Palumbo as Chairman of the Board, replacing Yoav Shaked, who remains a director. The change is effective immediately, according to an SEC filing.
DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHea
DarioHealth Corp. (NASDAQ: DRIO) appointed John R. Palumbo as Chairman of the Board, effective November 3, 2026. Palumbo, with 40 years of healthcare experience, will join the Q3 2026 earnings call to discuss market shifts and strategic priorities. The company aims to lead the convergence of consumer and payer-funded healthcare, with a focus on chronic care management.
DarioHealth (DRIO) will release its Q3 2026 financial results on November 12, 2026, before market open. A conference call and webcast will follow at 8:30 a.m. ET. Executives including CEO Erez Raphael will discuss the results. The company focuses on AI-powered healthcare technology for chronic condition management.
BTIG initiated coverage of DarioHealth with a Buy rating and $6 price target, implying 76.5% upside from the Oct 26 close. The firm cites strong clinical evidence, high customer engagement, and expanding market access as key strengths.
DarioHealth (DRIO) announced a contract extension with a regional grocery retailer to offer menopause care to employees, starting in January 2027. The client, with over 19,000 employees, has used Dario's cardiometabolic solution since 2025 and selected Dario's newly-launched women's health program based on employee demand. The expansion is expected to increase revenue and improve health outcomes, according to the company.
DarioHealth (DRIO) announced an Aon review estimating 2.5% to 7.2% annual healthcare cost reductions across a covered population, with $5,077 annual savings per type 2 diabetes user. Aon's analysis, based on 17 studies identified by Dario, suggests potential savings of $3.8M to $10.8M for a 20,000-life population. Aon did not independently verify the data.
DarioHealth (DRIO) secured a contract with a major New Jersey health plan covering 1.5 million lives, via partner Amwell. The deal, part of Dario's channel strategy, is expected to launch and generate revenue in Q1 2027, expanding its reach into large health plan populations.
